Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal research without human clinical data
PubMed 35307861 · doi:10.15252/embj.2021110466
What was done
Researchers evaluated ketone body metabolism in pancreatic ductal adenocarcinoma (PDA). They compared metabolic gene expression in spontaneously arising PDA tumors from mice against normal pancreatic tissue. In vitro assays assessed the impact of HMG-CoA lyase (HMGCL) knockdown on PDA cell migration, invasiveness, and tumor sphere compaction. In vivo mouse models were used to measure the effect of HMGCL disruption on primary tumor growth and the effect of β-hydroxybutyrate (βOHB) on liver metastasis.
What was found
The abstract provides directional outcomes without exact numbers, effect sizes, or confidence intervals. HMGCL was identified as one of the most deregulated metabolic enzymes in mouse PDA compared to normal pancreas. In vitro, HMGCL depletion impeded cell migration, invasiveness, and sphere compaction. In vivo, HMGCL disruption decreased PDA tumor growth, and βOHB stimulated metastatic dissemination to the liver.
Why it matters
This study demonstrates that PDA cells can adapt to nutrient stress through ketogenesis, highlighting HMGCL and β-hydroxybutyrate as potential metabolic targets to impede pancreatic cancer progression.
Limits
The study is restricted entirely to cell culture and animal models, with no clinical human data reported in the abstract. Sample sizes (n), quantitative statistics, and precise effect sizes are omitted. Clinical relevance to human dietary ketosis or systemic ketone levels remains untested.
Cited by
- supports Certain types of cancer cells can utilize ketone bodies and accelerate their growth in response to them.